[The effect of fraxiparin on thrombocytic-vascular hemostasis in patients with unstable stenocardia].
Clinical examination of 25 males with new-onset and progressive angina pectoris resistant to inpatient combined antianginal treatment versus 15 healthy males established hyperfunction of the platelets in low antithrombogenic activity of the vascular walls in patients with unstable angina pectoris. A 5-day course of fraxiparin resulted in a trend to a decrease in ADP-induced platelet aggregation and in the level of platelet factor IV. The endothelium recovered normal antiaggregation and fibrinolytic properties. This may underlie the drug efficacy against unstable angina pectoris.
Timofeeva
A V
AV
Dobrotvorskaia
T E
TE
Dolgov
V V
VV
Arifullin
Sh S
ShS
D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy*; D001792:Blood Platelets / Q000187:drug effects*; D001808:Blood Vessels / Q000187:drug effects*; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017762:Nadroparin / Q000008:administration & dosage / Q000494:pharmacology*
D017762:Nadroparin
Vliianie fraksiparina na trombotsitarno-sosudistyĭ gemostaz u bol'nykh nestabil'noĭ stenokardieĭ.